China NT Pharma Group Issues Supplemental Profit Warning: Loss Reduction Expected for FY2025

Key Highlights

• Reduction in Expected Net Loss for FY2025:
  China NT Pharma Group Company Limited (“China NT Pharma” or “the Company”) has revised its previously announced profit warning. The Group now expects its net loss for the year ended 31 December 2025 to be in the range of approximately RMB10.9 million to RMB15.9 million, representing a further reduction from the loss previously disclosed.
• One-Off Non-Cash Gain Recognised:
  The reduction in loss is primarily attributable to a one-off non-cash gain of approximately HK\$15.4 million (equivalent to RMB14.1 million). This gain is related to the issue of new shares for the settlement of debt, as confirmed during ongoing discussions with the Company’s auditor.
• Board Meeting and Results Announcement:
  The Company’s board meeting is scheduled for Tuesday, 31 March 2026, during which the annual results for FY2025 will be considered and approved. The audited results announcement will be published on the same day.

Details and Implications for Shareholders

China NT Pharma’s supplemental announcement provides a significant update for shareholders and potential investors regarding the Group’s financial position for FY2025. Following further audit work and discussions with the Company’s auditor, the Board now expects to recognise a one-off, non-cash gain due to the issuance of new shares aimed at settling existing debt. This gain will reduce the anticipated net loss for the year by approximately HK\$15.4 million (RMB14.1 million), compared to the previously issued profit warning.

As a result, the revised expected net loss for the Group is now RMB10.9 million to RMB15.9 million. This represents an improvement in the Group’s financial outlook and may be viewed positively by the market, as it signals effective management of debt and a stronger balance sheet.

All other details and information from the profit warning announcement dated 26 February 2026 remain unchanged. Shareholders are strongly advised to review the full audited annual results, which will be released on 31 March 2026, for a comprehensive understanding of the Group’s financial position.

Potential Price-Sensitive Information

• The recognition of a non-cash gain reducing the net loss is a potentially price-sensitive development, as it directly impacts the Company’s profitability and could influence investor sentiment and the share price.
• The use of new shares to settle debt may also affect the share capital structure and could have longer-term implications for current shareholders’ equity.
• Investors should exercise caution and closely monitor the audited results announcement for any further material information.

Board and Management Update

The Board currently consists of Executive Directors Mr. Ng Tit (Chairman) and Ms. Ng Anna Ching Mei; Non-Executive Directors Dr. Qian Wei and Ms. Chin Yu; and Independent Non-Executive Directors Mr. Yu Tze Shan Hailson, Mr. Ng Ming Kwan, and Dr. Zhao Yubiao.

Investor Advisory

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professional or financial advisers.

Disclaimer: This article is a summary and interpretation of official announcements made by China NT Pharma Group Company Limited. Investors should refer to the Company’s official publications and audited results for complete and accurate information. This article does not constitute investment advice. The author and publisher accept no liability for any loss arising from reliance on the information contained herein.

View NT PHARMA Historical chart here